Skip to main content

Advertisement

Table 2 Efficacy evaluation on Day 28 after PCR correction* Intention-To-Treat Analysis

From: Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial

Efficacy evaluation AS-SMP
3 days
(N = 476)
AS-SMP
24 hours
(N = 458)
AL
3 days
(N = 450)
Possible failure – n (%, 95%CI) 15(3.2%,1.8–5.1) 26 (5.7%,3.7–8.2) 33(7.3%,5.1–10.1)
ETF – n (%) 0 0 1(0.2%)
LCF – n (%, 95%CI) 3 (0.6%,0.1–1.8) 2 (0.4%,0.1–1.6) 0
LPF – n (%) 0 0 0
ACPR – n (%, 95%CI) 457 (96.0%,93.8–97.6) 429(93.7,91.0–95.7%) 414 (92.0,89.1–94.3%)
  1. *Possible failure: lost to follow-up or withdrawal (a subject** who received high dose of treatment or subjects antibiotics with anti-malarial activity or malaria smear results invalidated after quality control) or subjects for which filters paper were not analyzed or were undetermined result by PCR
  2. **One subject received on day 0 one dose of a junior tablet of AS-SMP instead of a baby tablet as described in the study procedures and treatment. There was no adverse event found to be related to that misuse of the study drug.